BioForce targets NIH (National Institutes of Health) grant at NanoArray technology:
This article was originally published in Clinica
BioForce Nanosciences will use a $500,000 grant from the US National Institutes of Health to develop its Nanoarrayer molecular deposition tool, a technology for creating miniaturised biological tests. The technology, which places thousands of molecules at defined locations on a single microarray spot, allows for the development of a broad spectrum of ultra-sensitive, ultra-miniaturised biological tests, such as blood screens and the detection of pathogenic material, says the Ames, Iowa firm.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.